Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy).
What does NSF stand for?
NSF stands for Nephrogenic Systemic Fibrosis
This definition appears very rarely and is found in the following Acronym Finder categories:
- Science, medicine, engineering, etc.
See other definitions of NSF
We have 229 other meanings of NSF in our Acronym Attic
- Natural Solutions Foundation (est. 2004)
- Naval Stock Fund (US Navy)
- Naval Support Facility
- Naval Surface Fire
- Navy Stock Fund
- Near Side Front (automotive suspension)
- Nederlandse Sport Federatie
- Nederlandse Strandzeil Federatie
- Needy Student Fund
- Neighborhood Street Fund (Seattle, WA)
Samples in periodicals archive:
We will also discuss specific issues related to MRI, such as allergic reactions to gadolinium chelates, side-effects of gadolinium, nephrogenic systemic fibrosis (NSF), and its use in patients with renal failure and on dialysis.
Nephrogenic systemic fibrosis (NSF), unknown before March 1997 and first described in 2000, is a systemic disorder characterised by widespread tissue fibrosis.
Kidney patient Margaret Roxburgh, 54, was diagnosed with nephrogenic systemic fibrosis days after being injected with Omniscan.
Nephrogenic systemic fibrosis (NSF) is a recently identified fibrosing disorder affecting patients with chronic kidney disease and occasionally those with acute renal failure.
The requested warning would state that patients with severe kidney insufficiency who receive gadolinium-based agents are at risk for developing a debilitating and potentially fatal disease known as nephrogenic systemic fibrosis, or NSF.
Contrast-free imaging is particularly important because gadolinium, the most common contrast agent used for magnetic resonance imaging (MRI) and magnetic resonance angiography (MRA) exams, has been directly linked to a sometimes fatal disease that occurs in patients with renal insufficiency, called Nephrogenic Systemic Fibrosis (NSF) or Nephrogenic Fibrosing Dermopathy (NFD).
In compliance with recommendations issued by national, European (EMA) and US (FDA) drug safety agencies, product leaflets and prescribing information for gadolinium-based contrast products contain information on the risks of nephrogenic systemic fibrosis (FSN).